$TCON Bullish run up into earnings Nov 5 th.

Long

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON)

NASDAQ:TCON TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, ophthalmic, and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types; TRC205 created for the treatment of fibrotic diseases; and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.

Bullish on move above 50MA
Average analysts price target $1.67
Overweight rating.

⭐⭐⭐ Sign Up for Free ⭐⭐⭐

1) Download our Mobile App >>

Android: dexwirenews.com/APP

Apple: dexwirenews.com/iOS

2) Join our Telegram >> t.me/DEXWireNews

3) Follow @DEXWireNews on Social Media

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.